Alternatively genetically modified TCRs could be used to target BIRC5 expressing cancer cells [60], especially because of its wide overexpression in a number of tumour types including leukaemia and with regard to this study AML. The gene discussed is BIRC5; the disease is acute myeloid leukemia.